Ralph Cincinnati
Nurse Practitioner · Wyomissing, PANPI 1174580716
Payments from drug & device makers
Across 704 payments — averaging $23.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$3K
- Senseonics, Incorporated$2K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- AbbVie$1K
- Abbott$1K
- plus $7K from 29 others
What the payments were for
- Speaking & faculty fees$3,70022%
- Travel & lodging$680%
- Food & beverage$12,65777%
- Education$530%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 56 | $3,012 |
| Senseonics, Incorporated | 3 | $1,800 |
| Lilly USA, LLC | 90 | $1,415 |
| AstraZeneca | 42 | $1,200 |
| AbbVie | 69 | $1,116 |
| Abbott | 57 | $1,033 |
| Boehringer Ingelheim | 40 | $896 |
| Novo Nordisk | 45 | $792 |
| Sanofi-aventis U.S. LLC | 46 | $733 |
| Bayer | 22 | $470 |
| Amgen | 34 | $446 |
| Insulet Corporation | 14 | $413 |
| Corcept Therapeutics | 19 | $358 |
| Amarin Pharma, Inc. | 46 | $347 |
| Medtronic | 13 | $327 |
| Dexcom, Inc. | 12 | $304 |
| Merck | 17 | $280 |
| Xeris Pharmaceuticals, Inc. | 11 | $227 |
| Tandem Diabetes Care, Inc. | 14 | $208 |
| Ascensia Diabetes Care US Inc. | 6 | $186 |
| Novartis | 8 | $172 |
| Zealand Pharma US, Inc. | 6 | $134 |
| Cequr Corporation | 5 | $99 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $93 |
| Esperion Therapeutics, Inc. | 5 | $79 |
| Sequel Med Tech, LLC | 2 | $54 |
| Kowa Pharmaceuticals America, Inc. | 4 | $52 |
| BD | 2 | $51 |
| BETA Bionics, Inc. | 3 | $44 |
| Averitas Pharma Inc. | 2 | $44 |
| Alfasigma USA, Inc. | 2 | $27 |
| Bigfoot Biomedical Inc | 1 | $22 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Embecta Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,479 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 525 | $881,824 |
| MounjaroTirzepatide | 439 | $572,576 |
| KorlymMifepristone | 16 | $522,699 |
| JardianceEmpagliflozin | 327 | $375,512 |
| Tresiba Flextouch U-200Insulin Degludec | 294 | $339,813 |
| FarxigaDapagliflozin Propanediol | 265 | $291,890 |
| TrulicityDulaglutide | 139 | $255,055 |
| GlyxambiEmpagliflozin/Linagliptin | 213 | $199,381 |
| TradjentaLinagliptin | 136 | $155,335 |
| JanuviaSitagliptin Phosphate | 111 | $133,539 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 114 | $132,822 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 83 | $114,989 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 97 | $113,242 |
| RybelsusSemaglutide | 60 | $104,782 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 84 | $94,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $792 | $1,083,669716 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,415 | $844,940625 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Trijardy Xr, Jentadueto Xr | $896 | $817,193758 claims |
| Corcept TherapeuticsKorlym | $358 | $522,69916 claims |
| AstraZenecaFarxiga | $1,200 | $291,890265 claims |
| MerckJanuvia, Janumet Xr, Janumet | $280 | $262,528233 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $733 | $46,82433 claims |
| AbbVieSynthroid | $1,116 | $6,704106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Wyomissing
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.